Laboratorios Stein S.A.

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Sugemalimab(Cejemly)
Phase 3
PD-L1Monoclonal antibody
Non-Small Cell Lung Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
December 2029 (1)
Sugemalimab · CejemlyPhase 3Extranodal NK/T-cell Lymphoma
Est. primary completion 2029-12 · NCT05700448 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.